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THE OPIOID EPIDEMIC
REGULATION, RESPONSIBILITY, AND REMEDIES
Tricia Herzfeld
Gerald Stranch
Zack Buck
MR. GROVES: My name is Alan Groves. I served
as the Editor in Chief of the Tennessee Journal of Law
and Policy from February 2017 until just a few weeks
ago. My successor Editor in Chief will be moderating our
second panel this afternoon. Our first panel discussion
today is going to focus on some of the questions you all
were asking at the end of the last session about
regulation, responsibilities and remedies. So, our first
two panelists to my immediate right come from the firm
of Branstetter, Stranch and Jennings located in
Nashville, Tennessee. In the past year, their firm has
filed three different lawsuits in Tennessee against
several opioid manufacturers. Tricia Herzfeld is a 2001
graduate of George Washington University Law School
and is now a partner at Branstetter, Stranch and
Jennings. Ms. Herzfeld has previously served as Legal
Director of the American Civil Liberties Union of
Tennessee where she successfully litigated dozens of
high-profile civil rights cases in state and federal courts.
She has also served as a public defender in Miami where
she conducted over 80criminal trials. In 2012, she was
selected as one of the nation’s Super Lawyers, and among
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those with that honor, she attained Rising Star status in
2013.
Her colleague, Gerald Stranch, received his law
degree from Vanderbilt University. He is now the
managing member of Branstetter, Stranch and Jennings
and chairs the firm’s complex litigation team. He
oversees the firm’s securities, class actions, antitrust,
shareholder derivative, mass tort and consumer class
cases. Mr. Stranch also served as an adjunct professor at
Vanderbilt University School of Law. He was named the
top 40 under 40 from the National Trial Lawyers
Association and was named the Mid-South Rising Star by
Super Lawyers.
And finally, Professor Zack Buck at the end of the
table, teaches a variety of health law classes at the
University of Tennessee College of Law, including a
bioethics and public health seminar, torts, health care
finance and organization, health care regulation and
quality, and health care fraud and abuse. His scholarship
examines governmental enforcement of laws affecting
health and health care in the United States. Before
joining UT, Professor Buck taught at Mercer University
School of Law, Seton Hall University School of Law and
the University Pennsylvania School of Law. He also
practiced complex commercial litigation at Sidley Austin
in Chicago.
So, with this distinguished panel now introduced,
let’s just jump right into our first question, and we are
going to start off where the last panel ended talking about
remedies and particularly the search for a cause of action
in some of these lawsuits that have been filed.
So, Ms. Herzfeld, I’ll throw this first question to
you. Can you talk to us a little bit about the suits that
your firm has filed and particularly why you chose to
bring those causes of action that you did, the statutory
and the common law public nuisance claims and then
also a cause of action under Tennessee’s Drug Dealer
Liability Act.
[318]
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MS. HERZFELD: Sure. Thanks very much for
having us. We appreciate the opportunity to talk about
our lawsuits. Lawyers always like to talk about their
lawsuits, so we can answer any questions you all have,
and we happily do so. Our lawsuit that we brought− we
have actually brought three different lawsuits
throughout Tennessee. They have been filed in the
Tennessee state courts. So that means our lawsuits are a
little bit different than the vast majority of them across
the country. Those have been filed primarily in federal
court or have been moved to federal court. So, we made a
very, very rational, I think, and determined decision that
we wanted to keep our cases in state court, and there
were some reasons for that. We don’t think that a federal
judge, with all due respect to the federal judiciary in
Cleveland, Tennessee, where the multi−district litigation
is, is going to have the same understanding of the real
day-to-day impact of the opioid crisis. So, we really made
a point to file our cases in Tennessee.
So, the first case that we filed is in Sullivan
County, Tennessee, so up in the very, very top corner in
the Appalachian region where it is really ground zero to
the opioid epidemic here in Tennessee. They have the
number one statistics for births of children that are born
dependent on opioids, and so those children are classified
as having neonatal abstinence syndrome, and that was
the primary reason that we decided to file that first case
there. Our cases are a little bit different than many of the
others, because ours has primarily been filed by District
Attorney Generals, and I think you are going to hear from
one of our clients a little bit later today. We did that
because we have a somewhat unique− I say unique, sort
of− statute in Tennessee called the Drug Dealer Liability
Act. Now, the Drug Dealer Liability Act initially was put
together by an organization called ALEC. Has anybody
heard of ALEC? American Legislative and Exchange
Council.
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So, they put together somewhat conservative
proposed legislation and kind of pushed that legislation
out throughout the country. I think it was 23 states ended
up passing various versions of the Drug Dealer Liability
Act back in the day, and Tennessee was one of them.
Now, initially the Drug Dealer Liability Act was
supposed to− I think the thought process at that point
was, there was a crack cocaine epidemic, and the idea was
to be able to go after the higher−level drug dealer chain,
not just the person you’re buying from or the person at
the drug house, but kind of going up until you get to the
suppliers and the producers, further and further. So, we
took that law and decided, well, it kind of seems like the
same thing for opioids; right? You have the street-level
dealers. You have the people that they are getting them
from. You have the pill mill doctors who are supplying
them, which is often without a legitimate prescription;
that’s mostly how that happens. They get them from
various pharmacies, who get them from distributors, who
ultimately get them from producers. And why is that any
different than a drug cartel? So that’s why we decided to
file under the Drug Dealer Liability Act, because,
truthfully, we think the opioid epidemic and the way that
it’s impacted Tennesseans and most of the state, it really
is illegal drug activity; right? That’s really what we’re
talking about. It may have the veneer of being legal,
because there are legal uses for opioids, but the legal uses
of opioids are not what is causing this epidemic and
causing so many people to die. It’s the illegal uses.
So, we’re really trying to tackle it from that way.
Now, the Drug Dealer Liability Act has a lot of benefits
to it. One of them that we really like is, there’s not that
level of causation. So, the principles of this law are more
actually rooted in antitrust, so it’s market participation.
So, all we have to prove− all we have to prove− is that
someone or a corporation knowingly participated in the
illegal drug market, and as you have heard earlier, with
those numbers, how could you not have known; right? I
[320]
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mean, the diversion is clear, the news stories are clear;
we simply have to prove that they knowingly participated
in this illegal drug market. Now, a lot of other causes of
action shave been filed, a bunch of other different
lawsuits across the country. They are more of a
traditional negligent standard, where you would have to
prove in this context that this individual got this pill from
this person, there was a duty, there was a breach, and
you’re going to have to work your way all the up pill by
pill all the way through. That’s not required under the
Drug Dealer Liability Act. So that’s why we chose that
cause of action. The other one that we filed is, we filed
under common law and statutory nuisance, and you will
see nuisance showing up in a lot of the lawsuits
throughout the country. Specifically, for us, our District
Attorneys typically file nuisance lawsuits. They are the
ones who file those. They shut down houses of
prostitution. They shut down crack houses. They do this
stuff all the time. So, it meshed very well with an
additional cause that is typically within their purview
infighting crime. So, the purpose of our lawsuit is to focus
less kind of on consumer protection, more to really focus
on the fact that these drugs are now being used illegally
and everybody knows it.
MR. GROVES: Mr. Stranch, I’ll throw the next
question to you. Ms. Herzfeld just talked about the state
law claims that your firm has brought, the Tennessee
Drug Dealer Liability Act and then the common law and
statutory public nuisance claims. Some attorneys for the
opioid manufacturers have argued that federal
regulations actually preempt any state law claims. So,
what is your response to that argument?
MR. STRANCH: Those defense lawyers are
saying anything and everything they can to try to shut
this litigation down. They are absolutely shameless. They
are even attacking whether cities and counties have the
[321]
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authority to bring the lawsuit or to hire outside counsel
to do it. Their entire strategy right now is delay, delay,
delay as long as possible. I don’t think the federal
regulations preempt anything in our litigation in
particular, because we have specific state statutory
claims that don’t talk, reference or have anything to do
with federal regulations. One thing that’s clear is, this is
not a complete preemption area like an ERISA where any
claim at all would be preempted− field preemption is
what it’s called. They have not really raised federal
preemption in our case in the motion to dismiss that we
already argued. They did throw in the rest of the kitchen
sink, though. Some of the other cases that are out there
might have more of a federal preemption issue,
particularly with the distributors; the McKessons, the
Cardinals, the AmerisourceBergens, those entities,
because those claims are often based on− you have this
federal duty that you have to report when certain key
things occur, you didn’t report, so now I’ve got a cause of
action against you, and so you might run into some
preemption issues on that. We have chosen not to file the
distributor cases yet until we can get the discovery so we
can point to exactly what they knew and when they knew
it so that we can plead around and avoid any possible
problems with preemption. But, again, it’s not really as
much of an issue for our case, because we are not trying
to prove you knew about this through federal regulation.
We are saying, hey, look, you not only participated in the
illegal drug market because you continued to ship pills to
known diversion sources. So, it’s completely outside of
that realm. And so, we’re a little bit different in what we
do. But, yes, they are raising any and all defenses that
they can to delay this as long as possible.
MR. GROVES: Thank you. Ms. Herzfeld, you
mentioned the remedies that are available for some of
these causes of action. Can you talk about what kind of
damages that you are hoping to obtain for the clients that
[322]
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you represent, and are there any procedural or legal
obstacles that you face in obtaining those damages?
MS. HERZFELD: So, we are hoping to obtain
really big damages for our clients, huge, huge, and there’s
a lot of reasons for that, not because anybody is trying to
get rich; right? When you look at these towns and you
look at− Sullivan County, Tennessee, is a great example.
I think someone in the audience said earlier that the
towns are emptier. They are full of people that can’t get
jobs, because nobody can pass a drug test, and that’s
nobody’s fault; right? I mean, it’s not because you decided
that you were going to become a drug addict and that’s
how you wanted your world to end up. Nobody intends to
become a drug addict. But you did have a workplace
injury because you worked in the coal mines or you
worked wherever it is, and your doctor gave you these
drugs. Nobody intends to get addicted. Nobody intends to
become a drug addict. And the consequences of that are
just devastating, especially in a small town. We know
that there are employers that have jobs they can’t fill
because they cannot find sufficient people to pass a drug
test. So, our case not only includes damages for the town,
which I’ll talk about more specifically in a minute, but
also claims for babies. So I think our case is the only
casein the country, at least the last time I checked, where
we have included claims on behalf of particular infants,
and these are individual children whose identities are
sealed; I know who they are, but their identities are
sealed, and they were babies that were born dependent
on these drugs, so their birth mothers took the drugs
during pregnancy and at some point gave birth to these
children who suffered enormously.
So, I would like to talk about their damages first.
What we know about the children that are born with
neonatal abstinence syndrome is actually, pardon the
pun, in its infancy. It’s not something that has been
studied for an extraordinary amount of time, but this
[323]
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phenomenon, neonatal abstinence syndrome and opioids,
hasn’t been around that long. Here’s what we know:
When these babies are born, they shake, they cry
uncontrollably, you cannot sooth them. That is the one
thing you will hear everyone say. They scream and
scream and scream to the point where their volunteers
whose only job is to cuddle the babies. They just walk and
cuddle and rock and walk and cuddle and rock. And why
is it? Because the children have had a constant supply of
these highly-addictive medications in utero, and once
they are born, it’s discontinued. Do you know how they
treat those babies? Morphine. They have to give those
babies morphine. In the first days of their life, they are
given a bit and then they wean them down and they wean
them down and they wean them down, and so they end
up in the neonatal intensive unit and they are being
given controlled doses of morphine to wean them down.
So that’s the first few weeks, which is crying and shaking
and rocking and horrible. But then what comes next? You
have a lifetime of learning disabilities: oppositional
defiant issues, inability to concentrate, emotional
outbursts that they don’t understand why that is
happening; the parents, the grandparents, foster
parents, no one understands why this child is just not
behaving in a way that makes sense, and what we’re
finding, through the studies, is that most of that can be
taken back to this exposure in utero. Babies are
developing; there’s stuff that happens there. So, we are
trying desperately to get damages for those babies. We
know that they will have a lifetime of medical needs, a
lifetime of special needs. They need early intervention.
The educational costs, imagine the educational costs of
taking a child with needs. We don’t quite understand
through essentially 20 years. We don’t know what that is
going to look like. And Tennessee has the highest number
of babies born with neonatal abstinence syndrome due to
opioid addiction.
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MR. STRANCH: It’s a baby born every other day
dependent on opioids.
MS. HERZFELD: It’s so bad that the Children’s
Hospital up there had to open up its own wing, its own
wing with its own beds just for these babies. So, I don’t
want to lose sight of that. Of course, we’re filing through
District Attorneys who are seeking truth and justice and
going to get the bad guys and drug dealers out of their
districts; right, and that’s true and important and
amazing, but also, it’s the babies; right? It’s the people
who are raising the babies. It’s the families that are
broken and destroyed by the fact that now the
grandmother or the auntie or the cousin that’s raising
these babies. And when you take that, and you multiply
that not just from a one-family perspective, but from an
entire community, the devastation is extraordinary. So
what kind of damages are you hoping to get? Well, let’s
see, prosecutors have to spend more time prosecuting,
cops have to spend more time arresting, more Narcan,
more ambulance costs, more emergency room costs, more
overdose costs, more educational costs. Court system
costs go up; right? Everything exponentially goes up.
Those resources might have been used for other things,
positive things, but instead they are all being diverted to
deal with this completely overwhelming crisis.
So, what are the damages? Good question. They
are enormous. The other thing we have asked for, in
addition to damages to fix all the stuff that’s happened in
the past, is, we have asked for injunctive relief going
forward, and that sounds crazy; right? How do you get
injunctive relief on a pill epidemic, an illegal pill
epidemic? But that’s what we want. We want the drug
manufacturers to stop. That’s just the answer, stop, stop
doing it. You know what you are doing, you know what
the harms are, stop putting profits over people, stop. And
if that means that they have to pay for remediation in
order to make these things happen, in order to not only
[325]
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make the communities whole for the past damages, but
to pay for rehab beds, education, different drug courts,
these types of things going forward to kind of help fix that
damage, special ed students, all these things, they all
need to pay that going forward. So, the damages are
huge, and I think it will probably be a bit challenging to
figure out exactly how big, because there’s a lot of zeros
there.
MR. STRANCH: One of the things you need to
know about that, like in Hawkins County, the sheriff did
an analysis at the jail. Eighty-eight percent of the jail
population, which was full, was there because of pills,
either DUI while high on pills, stealing to buy pills,
domestic violence while high on pills. It’s all pills. It’s 88
percent of the jail in Hawkins County. And so, we really
can’t emphasize enough how bad this is in the
communities. It’s easy when you’re in a city like
Knoxville to miss exactly what’s going on in some of these
smaller communities.
MS. HERZFELD: We missed it. We didn’t know;
right, until we knew? I mean, we didn’t know until we
knew. It’s devastating.
MR. GROVES: Professor Buck, we have heard a
little bit about the suits against these drug
manufacturers. Just from a broader public health
perspective, what are the similarities in this type of
litigation against the drug manufacturers to the
litigation that occurred against Big Tobacco in the 1990s,
and are there any differences?
MR. BUCK: Sure. So, focused on manufacturers
for a minute and talking federal regulations. I think
there’s one kind of major similarity, and that is, in many
of these claims that are the federal claims, there is a core
to them that focuses on some kind of fraudulent
[326]
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advertising. So the drug companies are actually
advertising these drugs either direct to consumer or in
doctors’ offices in some way that can be alleged to be
fraudulent, and in that way we have a similarity with Big
Tobacco in the 1990s. You know, they’re burying bad
science, they’re minimizing poor results from clinical
trials, and they may be actually misbranding these drugs
through their misleading advertising. But beyond that,
there are a lot of differences, and in particular there are
three that I was able to kind of come up with in thinking.
First, opioids have a lot of regulation around them to
begin with. They actually are FDA approved to treat
chronic pain, and we have been talking a lot about misuse
of opioids and illegal use of opioids, but I think it’s
important to also recognize that through the last
generation of health law and policy, there’s been a lot of
discussions about how chronic pain in this country is
undertreated and how individuals have a stigma
attached to them who are facing chronic pain, as well as
the individuals who prescribe those drugs, and that’s
complicating the regulation of these drugs in a way that
never complicated the regulation of tobacco. Tobacco was
not subject to FDA approval until 2009 in this country.
Drugs that are sold in this country are approved by the
FDA, and so we have a regulatory structure in place from
the federal perspective that is different than tobacco in
that regard. The second I guess you could say a way that
these are very different is that these drugs are subject to
a number of antifraud tools at the federal level when
we’re talking about manufacturers. So, the most potent,
you can talk about the False Claims Act.
The federal government is able to go after
manufacturers who misbrand their drugs, who advertise
their drugs to doctors in ways that are untrue, because
the federal government pays for these drugs through
Medicare and Medicaid, and these programs allow the
federal government to empower the Department of
Justice to go after manufacturing companies who make
[327]
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untrue statements in their advertisement. The problem,
of course, with this way or this pathway is that there’s
often a desire to settle these cases, particularly of course
from the drug companies’ perspective, but also from the
Department of Justice. There’s been a reliance on
Corporate Integrity Agreements over the last couple of
years that are put in place to try to govern drug
companies’ behaviors going forward and check in every
quarter on pricing or advertising. And I think the biggest
challenge here is that misbranding is really profitable for
these manufacturing companies. So if you’re a
manufacturing company and you have gotten your drug
approved for a narrow segment of the population, but you
can go into a doctor’s office and allegedly talk about an
off−label use that the FDA has not approved your drug
for, which is the case in the Purdue case around
Oxycontin, they were minimizing the addictive effects of
the drugs to the doctors; that’s the allegation. There’s a
huge market out there for which you do not have to go
through the FDA to seek approval. You can get doctors to
prescribe your drug off label, and often doctors will do so.
It’s a very profitable thing, if you are a private company
and you owe a duty to your shareholders to maximize
profits and you see that you can open up the market by
eight, nine, ten billion dollars and the statutory penalties
might only amount to a two or three-billion-dollar
settlement, that’s a calculation that many drug
manufacturing companies make. And so, I guess the
thing that I would say about this is that our enforcement
and regulatory system here is not potent enough and that
we settle too much with drug companies in this respect.
Of course, there’s also a challenge that if you take
a drug company to trial for one of these cases, what faces
them, in the event of a bad verdict from their perspective,
is exclusion from Medicare or Medicaid, and that means
they can’t basically do any business with anybody related
to the American healthcare system, to which they make
the argument to the Department of Justice this is
[328]
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something that will hurt a lot of people. Like the Pfizers
of the world going to court and saying we do a lot of good,
so you can’t exclude us because think about all the
patient harm that will come. And I know I’m blowing that
out of the perspective there, but that’s the heart of the
argument from the pharmaceutical company. The final
thing, the third I think big difference is going back to a
point that I had made earlier, which is a lot of these
drugs− and this is what makes this problem so
complicated and much more complicated than the tobacco
problem− is that, again, these drugs, some of them are
indicated, some of them are legitimate. We can’t
categorize them all in one way or the other. And we built
the system, at least in this country, around prescription
drugs that values professional autonomy, and it
complicates the regulation of prescription. We trust our
doctors and we give them a lot of authority and discretion
to make determinations about our drugs. And so, the best
way I think we can try to go about this problem is to go
after the manufacturers using the tools I mentioned. I
think those are the things that complicate the analysis
when we’re comparing it to tobacco.
MR. GROVES: Mr. Stranch, Professor Buck just
talked a little bit about the federal government’s
involvement from a regulatory perspective, but let’s talk
about what the Justice Department has done just in the
past year. In August of 2017, the Justice Department
announced the formation of the Opioid Fraud and Abuse
Detection Unit, which will temporarily provide financial
resources to 12 of the 94 U.S. Attorney’s Offices for the
purposes of prosecuting health care fraud and abuse, and
the Eastern District of Tennessee U.S. Attorney’s Office
was selected to participate. So how significant of a
development is this in your mind, and in general what
should the role of the federal government be in
combatting this crisis?
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MR. STRANCH: I mean, they’re putting drapes on
a burning house. You’re not going to arrest your way out
of this problem. It’s way too big. The time to do that was
25 years ago. And the federal government, there’s been a
complete failure of the regulatory system to do anything
about this, both at the state and at the federal level. I can
tell you, from representing District Attorney Generals,
that they are absolutely underwater with pill problems. I
mean, it’s the number one thing they deal with. We have
even got one DA that we’ve talked with who says, look, if
I dig hard enough on any case that comes into my office,
there’s going to be pills in there somewhere, I’ve just got
to dig deep enough to find it, and I take a little slightly
view, I say maybe in 99 percent of the cases, but he’s
adamant it’s a hundred percent. That’s how bad the
problem is. So, some funding to help find opioid fraud and
abuse and maybe shutdown a pill mill here or there, it
will be nice, it will help, but it’s− I mean, you’re standing
at a breaking dam and you’re sticking your finger in a
crack. It’s going to take the full weight of the federal
government, the state government, the court system
through private litigation and the legislature in changing
laws if we’re actually going to try to get ahead of this
problem, because right now we have not even hit the crest
of the tidal wave. It is still coming. It is still getting
worse. Every year there’s more babies born dependent on
opioids. Every year there is a rise in the number of deaths
due to overdoses. And even in places where we have seen
the overdose deaths start to level out, what we are seeing
is a number of overdoses have continued to rise anyway,
and what it is a reflection of is, now they have Narcan in
the cop cars, now they have Narcan in the ambulances,
so they can deploy immediately when something
happens.
We have got districts that we’re working with
where they’re putting it in schools because kids are
overdosing at school on opioids. So, a couple of million
bucks from the Department of Justice to put five or six
[330]
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people looking at pill mills is not going to change
anything. I mean, it’s a window dressing so that someone
can stand up and say, look, we’re doing something, but
they are not really doing anything at all. I will speak
briefly about Purdue for a second. They pled guilty to
misbranding back in 2006, and they admitted to what I
call the Holy Trinity of Lies. They said we told people that
if you have true chronic pain, you will not become
addicted to our pills. We told doctors and people if you
have true chronic pain, you won’t develop a tolerance to
our pills. And we told people if you have true chronic pain,
you won’t go through withdrawal when the pills are
taken away. They admitted in their criminal guilty plea
that those statements were all false and they knew they
were false at the time they made them, and these are
statements that they were training their people to go out
and detail doctors and tell them this over and over and
over again, and it went on for over a decade before the
federal government got involved on it. And during that
time, Oxycontin use went from a mid-eight figure drug to
a billion dollar drug every single year and created an
entire generation of doctors that believe these scientific
facts that are not facts that are in fact false, and it
created an entire generation of addicts, and despite that
guilty plea, despite paying $600 million that they paid as
part of that and agreeing that they’re not going to do that
and submitting to all these monitoring programs with
states and the federal government where they’re
supposed to submit, here’s the list of doctors that are
prescribing our pills at certain levels, there’s been no
enforcement action on that at all, and they have
continued to do the exact same thing. At the time we filed
our first complaint, they were still pushing OxyContin for
use in chronic pain, for people that have a history of
substance abuse and saying they probably would not get
addicted or less likely to get addicted. This is on web sites
that they run that they host with their name on them
that are designed for doctors to answer their questions
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about the drugs. The regulatory world failed, and they
have done nothing about it. And having a couple more
people in the U.S. Attorney’s Office who are focused on
pill detection and finding street−level drug dealers, it’s
going to do nothing.
MR. GROVES: In the second half of the discussion
I want to talk about some legislative policy proposals that
are percolating in the Tennessee General Assembly, but
before we get to that, Professor Buck, I’m going to throw
the ethics question at you. Rule 1.6(c)(1) of the Tennessee
Rules of Professional Conduct requires lawyers to review
information relating to the representation of a client to
the extent the lawyer reasonably believes disclosure is
necessary to prevent reasonably certain deaths or
substantial bodily harm. So, what are the implications of
this rule for attorneys that are representing the
pharmaceutical companies?
MR. BUCK: Well, I think that the reasonably
certain deaths or substantial body harm in 1.6(c)(1)
probably is not as applicable as you might think when
you take a look at it, because the individual that 1.6
contemplates is identifiable, and it’s hard to make that
causal link if you’re representing a pharmaceutical
company. I think that the ethical question that is perhaps
more interesting is, what if you find yourself
representing a pharmaceutical company that wants to
engage in some kind of activity that you think is
fraudulent. This happens a lot in the health care world
when I talk to people who practice, and it’s one of the
things that keeps them up at night. If our client
determines that they have gotten overpaid by Medicare
or if they find that some of their scientific statements
aren’t defensible, what is my role as the attorney?
Tennessee’s rules are permissive in that instance,
so you, as the attorney, have the ability to disclose, it’s
not required, but it is available to you if you think that
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you need to in order to prevent an ongoing crime or fraud.
And withdrawal also is permissible, and so in the event
that you might find yourself advising a client that’s
unwilling to reconsider a course of action, the withdrawal
would be permissive. There are cases in which
withdrawal is required, and that is when you know that
your client is using your services to perpetrate a crime,
so the line between those two standards is pretty blurry,
but usually there’s a lot of discretion given to the attorney
to decide what he or she needs to do in that instance, but
it is not an easy place to be in, and it happens I think
fairly regularly, so it’s worth thinking about when you’re
talking about the topic.
MR. GROVES: Now we will make that transition
and we’re going to talk more about legislative policy
proposals. As many of you might know, Governor Haslam
recently announced his Tennessee Together Plan, which
proposes a host of legislative and regulatory efforts to
fight this epidemic, and the plan emphasizes three
different strategies: prevention, treatment and law
enforcement. So, I want to spend the rest of our time
talking about this, and then at about 2:00, 2:05 we will
open it up to audience questions; you can be writing those
down. So, Ms. Herzfeld, some lawmakers in the General
Assembly have suggested that one way to prevent future
opioid addiction is to limit the supply and dosage of opioid
prescription such as what was mentioned earlier,
limiting new patients to a five−day supply. Others are
calling for prevention education in public schools. What
is your reaction to some of these preventative policy
proposals?
MS. HERZFELD: I think they are all really good
ideas, and they are very, very well intentioned, but I
think as Gerald has made it clear, we are really just kind
of nipping around the edges at this point. Legislation
alone isn’t going to fix the problem. I like the
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three−or−five−day limit on the ability to get those pills.
That is something that we have noticed is a really big
deal. The stuff that we have reviewed, I mean, just the
sheer number of pills that are given to folks, it’s crazy. I
mean, it’s a crazy amount, when you’re getting a
30−daysupply and five pills a day and four refills and
doctors don’t even worry about it; sure, you want another
refill, no problem. I had my tonsils out a couple years ago
and they had given me hydrocodone, I think, and of
course I had taken it for two days. I had my tonsils out;
right, in my 30s, and it was painful, but after the second
day, I was like my God, get me off of this stuff, like please.
When I went for my follow−up a week after, the
doctor is like do you want more hydrocodone? And I’m
like oh, my God, no. They just hand it out to you so easily.
And, again, I don’t think they mean anything by it. I
think they’re trying to be helpful, at least in some
circumstances. So, limiting that and limiting who can
prescribe I think is really another important thing. You
have a lot of nurse practitioners− and this is not to get
down on nurse practitioners− but you have a lot of nurse
practitioners who don’t have sufficient supervision who
are running things kind of on their own and you are
seeing an extraordinary number of these pills getting into
the system that aren’t necessary, they are not medically
necessary, it’s too much, it’s overkill, and a lot of that is
coming through nurse practitioners. So, there’s a lot of
things. There needs to be accountability; what is the
enforcement mechanism if somebody is violating. There
needs to be monitoring. There needs to be limitations on
all that. I don’t think it can just kind of be one thing and
here’s a little bit of education and we’re going to take the
pills and make it for five days. It has to be a more
omnibus kind of gigantic regulatory scheme to even begin
to make a dent.
MR. GROVES: Mr. Stranch, I was going to ask
you if you thought $25 million was enough to fund
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treatment and recovery services, but I think I know your
answer to that.
MR. STRANCH: Twenty-five million bucks won’t
even run a quality facility in one area of the state for a
year. Again, window dressing is all it is. What you need
to know about addiction when you’re dealing with opioids
such as this, you actually have multiple levels of addition
you have to break. You have to break the chemical
dependency. For many people in Tennessee, that is
actually broken while they are in jail, because they lose
the opioids, they go through withdrawal in jail.
Oftentimes they receive little to no medical care or
therapy as part of that process. They just literally detox,
go through the shakes, horrible diarrhea, headaches,
nausea, throwing up in the jailcell. That’s how it
normally goes. Once you break the chemical dependency,
you still have a behavioral dependency that has to be
broken as well, and your brain won’t go back to the way
it was before you started taking opioids for 12 to 18
months after you have broken the chemical dependency,
and so that’s why you have so many people that relapse
in that first year, because their brain is still not back to
normal and they’re feeling depressed, the hormones and
things inside your brain and the way it works and the
receptors are not working right again. They’re still not
back to normal, so it’s easy to slide back to the addiction,
because that feels good at that point. And so, if you really
wanted to do this correctly, I mean, you can look at
programs like the Tennessee Medical Association; they
have an assistance program for doctors that become
addicted.
It’s a multi-year program once you enter it, and
you lose your medical license if you don’t complete it.
They have an 85-percent cure rate, but it’s a multi−year
program. You have to go inpatient depending on the level
of your addiction. You have regular meetings with people.
You have regular drug tests. You have therapy on a
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regular basis, not like 12−step−type stuff, but like sit
down and talk about what’s going on in your life, what
are your triggers, help to identify your triggers so you can
deal with them, and $25 million is not going to let you do
that for a couple hundred thousand Tennesseans that are
currently addicted right now. Twenty-five million is not
going to let you do it for 400 or 500 Tennesseans in one
small area, and it’s certainly not going to provide the
aftercare once you break those addictions and you’re
trying to re-enter society as− as my father would always
say for me, I just want you to be a taxpayer− try to
become a taxpayer again. There’s no support services for
that. Twenty-five million dollars is nothing.
MR. GROVES: Professor Buck, part of the
Tennessee Together Plan also involves law enforcement,
and so the question that I have is, how do we enforce
criminal laws that are already on the books with respect
to users and distributors while also not re−enforcing the
negative stigma that is associated with addiction or
prescribing?
MR. BUCK: I think it’s a very hard question to
answer, so I’m just going to take up a couple minutes and
then we can go to the audience. But going back on what
was previously said, I mean, we don’t think about this as
a holistic problem, you think about physicians or dentists
prescribing these drugs and you ask yourself, well, why
would they? Well, first of all, they are seeking to treat
some symptom that you might have, but also, they are
incentivized to do that. We pay them to prescribe in this
country. Medicare pays more for drugs that are more
expensive to those doctors. They get a higher cut of the
cost. And so, until we actually look at our own laws that
actually create some of this problem in the first place and
reverse them, we’re not really going to make any dent in
the problem. In talking about the criminal aspect, I
mean, these issues that are so interesting find
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themselves on the line between public health and
criminal law, and I think part of the challenge is to
adequately calibrate the response.
Is it a public health problem or is it a criminal law
problem? I’m somebody who approaches these issues
from kind of a health policy perspective, and so I’m much
more likely to treat them at least on the addict side as a
public health problem. It reminds me of the case where
the students, common law students in here or others who
recently graduated, Ferguson versus the City of
Charleston that you might do in common law. It becomes
a Fourth Amendment case, but in that case the issue is a
hospital is testing the blood of pregnant women who
comes to the hospital against their consent, and then for
women who test positive, they are given the option of
either entering a drug counseling program or going to
jail. Now, if you think about that and apply a public
health lens, that’s a terrible program, because not only
does it penalize people who might need medical
assistance, but it deters people who need prenatal care
from coming to the hospital in the first place. So, the first
thing I would say to the governor is, do no harm, don’t
have a system in place that deters people from seeking
help that they need. And so, in that perspective, a public
health perspective, would say let’s put more money on
drug rehabilitation centers, let’s expand Medicaid in this
state, let’s provide care for people who need it who don’t
have access to these services, but I don’t think that’s the
total answer. I think the other part of it is, you have got
to calibrate the penalties for those that have the ability
to change their behavior, and that’s the manufacturers,
it’s the drug companies, it’s the distributors, and maybe
it’s the doctors; maybe we need to change the way we pay
physicians in this country, and also think about what we
can do to the regulatory mechanism. Is it really doing
enough to deter the pharmaceutical companies in this
country to think twice about advertising their drug in a
way that they can alleged to be fraudulent, even if it’s the
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case that they stand to make a lot more money if they do
so. So, I think we need to think about it from more of a
holistic perspective. I think you have to be really careful
that you don’t harm providing care for people who need it
by leaning too far toward criminality for those who are
struggling from addiction.
MR. GROVES: We will open it up to questions
now. I believe we have a couple of microphones that are
going to be walking around, so if you will just raise your
hand and I’ll call on you. I think right here in the front.
UNIDENTIFIED SPEAKER: Thank you. As an
attorney, if I’m working with the DPR and I’m being
accused of knowingly lying three times with regard to
relevant facts, even if I’m cooperating and remorseful, I’m
going to lose my license for some period of time at least,
and why do the manufacturers not lose their license for
some period of time at least when they knowingly mislead
and fraudulently tell things like that?
MR. STRANCH: Because our government is not in
the business of shutting down big business. They cut a
deal with them, they take some money, they let them
move on. I’ll give you an example of how bad it is. In our
lawsuit, we sent requests for admissions. Each one of the
facts that they admitted in that criminal guilty plea, we
asked them just to admit it in our lawsuit, and they
refused. They denied each one of them, said they are not
true facts.
UNIDENTIFIED SPEAKER: I was just
wondering, you had mentioned that there are kids
overdosing in schools now and I was wondering are those
primary, middle or high schools? What’s the frequency
that you all are seeing this now and where in the state,
which schools, what area is that happening?
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MR. STRANCH: It’s actually happening across
the country. It’s showing up in high schools. So, one of the
big things that’s going on is, school boards are now
discussing whether they want to deploy Narcan in the
high schools, because there’s been about a dozen or more
overdoses that have occurred in high schools where kids
would go to school, take a couple pills to help float their
math class and OD. It’s particularly becoming a problem
with the introduction of fentanyl and carfentanyl, which
is dangerously potent, and you don’t really know how
strong it is, because they’re pressing out pills to make it
look like something, sticking a little fentanyl in it, and
sometimes you’re getting a dose that’s ten times what you
think you’re getting. They had an outbreak down in
Florida recently where I think it was 12 students
0D’dand died where they were all taking the same pills
that were supposed to be one strength but were actually
about 10, 12 times that strength. And so, yeah, it’s
happening in high schools all over the country. I know
there’s been a couple of deaths in Ohio. There were the
deaths in Florida. We have talked to a couple people here
in Tennessee that are looking into it for their high schools
as well, as to whether they ought to be deploying Narcan
for suspected overdoses in the school. It’s a real problem.
MR. GROVES: We have another question down
here.
UNIDENTIFIED SPEAKER: This might be more
of a rhetorical statement or rhetorical question. I’m
thinking somewhat of an analogy to what’s happened
with the groundswell against the NRA for what
happened I guess a week and a day ago in Florida where
at least the kid seemed to be −− there seems to be some
friction, some impetus to fix. So, here’s my analogy, and
I’m not sure it works, and I’m wondering what you think
about it. So if I’m a doctor in Sullivan County, or a
dentist, and I’m figuring I’ve got, off the top of my head,
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a hundred colleagues, maybe 50, and I’m going to the
local county club once a month to meet with them just to
−− I don’t understand how the doctors in a smaller
community like that, why there can’t be some
groundswell from them that would be effective in
preventing this or something.
MS. HERZFELD: I think with a lot them, there
actually is. We have talked to an extraordinary number
of doctors who actually have an incredible amount of
remorse, who have unwittingly participated in this and
not realized. We were just talking about −−Gerald and
our other law partner, Jim, were telling the same story
about doctors who have said I have prescribed so much
opioids, I have given all these things, and now I’m looking
back going, oh, my goodness, how many people did I hook,
how many people did I harm, and they were talking about
two different doctors and two completely difference
conversations, which is wild; right? But it’s not. There’s
been a million articles− you can Google it− of doctors
sitting down and saying did I contribute to this, how did
I do this, and how do I get out of it, because now you have
patients coming to these doctors, and I’m talking about
the legitimate ones, I’m not talking about the Fentanyl
pill mills; that’s a drive−through business. It’s different.
It’s criminal. But for legitimate doctors, I mean, they are
now trained to ask what is your pain level; right? When I
was growing up, nobody asked that. It was how are you
feeling, what’s your blood pressure, looked at your heart
rate, blah, blah, blah.
But now it’s please rate your pain. So, we as a
society now expect the doctors to keep us out of pain, and
if you go to your doctor and say I’m in pain and I have got
this root canal, you haven’t given me enough medication,
you’re mad at your doctor for keeping you in pain, and
the truth of the matter is, he’s actually good; right? I
mean, not all the time and not an extraordinary amount,
but it is natural. There is a thing about pain. Sometimes
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you’re going to be in pain. That root canal is going to hurt.
So, I think that friction between the doctors and the
patients of I’m expecting you to make me feel better and
the doctor doesn’t want to give you something but yet
needs to give you a little something and there’s a dance
there. There have been some extraordinary things
written that you can find online where doctors talk about
that struggle.
MR. STRANCH: By the way, the whole focus on
pain and how we should never have pain, there’s all these
groups, Americans Against Pain, the American Society
for the Prevention of Unnecessary Pain, I mean, they are
all front organizations that have been funded by the
opioid manufacturers, and that’s what started this fifth
vital sign of your pain, because they want to be able to −−
they have something that they can justify, but it’s
completely subjective. My grandmother, for example,
every time she goes to the doctor −−she’s on her fifth bout
with cancer −− doctor says what’s your pain on a level of
one to ten. It’s ten. Every time it’s ten. The doctor finally
says to her, well, it’s always ten. She says, well, yeah,
either it hurts or it doesn’t. That’s what it is. That’s the
way she views it. And so, what this pain thing is, it gave
the doctors the ability to write down in the chart pain of
eight, oxycodone and give support for it, when it’s just a
completely subjective measure. There’s nothing objective
about it. It’s not like your blood pressure or your white
blood cell count or your temperature. It’s just a complete
subjective thing that is used to justify prescribing pills.
And they use these front groups to go in and train and to
talk to doctors that people should not be feeling pain on
a day−to−day basis. You should not ever feel pain, pain
is bad. Well, that was an actual sea change in the way
doctors view things.
I blew my knee out playing rugby in the ’90s and
had to have a knee surgery. When the surgery was done,
the doctor said to me afterwards, look, I’m going to give
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you this five-day prescription for pills, but I only want
you to take them when the pain gets to be too bad. The
pain is supposed to be your guide. It tells you what you
can and can’t do with your knee. If it hurts, stop doing
what you’re doing, because you’re going to over-extend
and reinjure yourself. That’s what the purpose of the pain
is. It’s a warning sign to you to don’t do that. And they
have completely changed that. And the doctor told me you
should probably only be taking these pills at night,
because you’re going to be worn out, your knee is going to
be hurting and it will help you fall asleep. That was it. A
friend had a very similar surgery last year. He got a 30day supply of Oxycontin and the doctor said, "And if you
feel any pain at all, you call me, and I’ll get you something
stronger." That’s the change, and it’s this emphasis on
pain that is not created through the medical community
by doctors doing largescale studies, blind studies, double
blind studies, observational studies, longitudinal studies,
it was created by a bunch of front groups that the opioid
manufacturers supported, because that’s how they can
push their pills.
UNIDENTIFIED SPEAKER: The first ten years
after law school, I did plaintiffs’ asbestos work and so I
know what’s in front of you and I wish you well. I’m
interested in causation and damages. Addicted children,
they don’t all have these horrible effects later in life. Now,
I’m in family law and I know that. So the test that we
were stuck with is, if you’re going to say− we were faced
with this: Okay, yeah, this guy has had all this asbestos
exposure, he has a much, much higher risk of contracting
cancer later on, but you have got to prove it’s more likely
than not that this guy is going to have cancer, so how are
you going to, A, prove that this baby is going to have
learning disabilities and obstructive disorder eight, nine,
ten years from now and there are kids that have learning
disabilities and obstructive disorder who never were
exposed to opioids? So, you have got to get over that too,
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that it’s this and he wouldn’t have just already had it, and
I can’t imagine how you’re going to do that. So how are
you going to do that?
MR. STRANCH: For starters, the Drug Dealer
Liability Act has a specific section that deals with
assigning claims to babies that are exposed in utero. So,
they have a specific test already for what you can do, and
we know for the kids that we filed, they already have
those problems now. They already have impulse control
problems now.
UNIDENTIFIED SPEAKER: How old are they?
MR. STRANCH: They range in ages. Most of them
are close to school age or in school.
UNIDENTIFIED SPEAKER: Some of them will
graduate from college before you’re through.
MR. STRANCH: More than likely, more than
likely. But one of the things that what we believe the
current state of medicine to be on this is, look, if you’re
exposed to significant amounts of opioids in utero, you’re
going to have impulse control problems later in life,
period, full stop, that’s going to happen. The question
becomes, are you able to deal with it, control it or not,
which is kind of ironic for someone with impulse control
problems, but the way it works is, you have to do early
childhood intervention and you have to work with the
children from day one and you have to provide them with
a stable environment so that they cannot have external
stressors. One of the problems of the opioid epidemic is,
of these babies that are born with NAS, like 25 percent of
them end up in foster care within a year. Many of them
end up bouncing in and out of foster care.
So, they don’t have a stable environment to start
with, which only causes to exacerbate the impulse control
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problems. Now, if a kid gets adopted straight out of
coming out of the NICU, goes to a stable, loving family
and they take care of him and they provide all of the early
childhood intervention, you may see a child that is going
to graduate and, as my dad said, become a taxpayer.
Greatest thing you could ever want for your kid is to
become a taxpayer. But that doesn’t mean that there’s
not going to be problems and struggles and the
behavioral therapy and other stuff that’s going to have to
be done along the way. We also know from another child
we represented that it can be much more than just
impulse control problems. It can literally be a question of
will this child ever be able to be a functioning member of
society without having to have an adult doing things for
them and overseeing them.
UNIDENTIFIED SPEAKER: The corporate boys
are going to say prove that this kid doesn’t need $1,000
worth of treatment rather than the$500,000 worth of
treatment that you say he needs ten, 15 years from now.
MR. STRANCH: We’re still struggling to get them
to admit they’re selling opioids. They’re not admitting
anything. But we’re going to have our experts that are
going to go through and that are going to talk about
what’s facing these kids, what’s going to happen, what
money is going to have to be spent on them, the problems
they’re going to have, and they’re going to have their
experts, like in all cases where you have medical experts,
who are going to say this kid was never harmed, and if
there was any harm, it was because the dad had bad
genetics or the mom had bad genetics and they all
preexisted and had nothing to do with this, and by the
way, would you like some opioids?
I mean, that’s what they’re going to do. And I just
think our experts are going to be more believable than
theirs, because we’re going to be putting them in front of
a jury that is going to be living in a community where
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they’re seeing this on a day−to−day basis, where they’re
seeing the disruption in the classroom through their kids
and their neighbors’ kids. Our first hearing that we went
to in our case, there was three divorces on the docket, and
two of them was because the spouse ran off because she
was addicted to pills. These communities know this, and
they are not going to be very impressed with a medical
doctor that comes in and says there’s no long−term harm
damage from shooting up opioids during pregnancy and
that these kids are not going to have any problems, and
if they do, it’s because they didn’t have a stable home life
beforehand and they’ve got bad genetics.
UNIDENTIFIED SPEAKER: Baby Doe is a very
sympathetic plaintiff.
MR. GROVES: That’s about all the time that we
have for this panel of discussion. Join me in thanking our
panelists for joining us.
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